Aminoglycoside Polymers in Combination Treatments for Triple Negative Breast Cancer (TNBC) Studies
Each year in Arizona, breast cancer causes two deaths and more than 4,600 diagnosed cases. Triple-negative breast cancer is diagnosed in 30% of breast cancer cases. This research involves the formulation of novel nanoparticle vehicles to effectively bind to DNA sites, stop cancer cell proliferation, and prevent cells from reviving. In the initial experiments, the dual drugs Mitoxantrone and Olaparib had 80-90% effective cell death. Various formulations of nanoparticles with novel polymers are being synthesized for effective cell death and minimal surrounding tissue damage. Protein expression studies in both in-vitro and in-vivo experiments are also being conducted.